![]() Three cohorts were used in these analyses. These adjusted MBDA scores were evaluated for association with radiographic progression and compared with each other and with conventional clinical and clinical/laboratory measures of disease activity. To account for the effects of adiposity, we used two surrogates to derive two metrics – the leptin-adjusted MBDA score and the BMI-adjusted MBDA score. In this study we evaluated the effects of variability in age, sex and adiposity on the MBDA score. Thus, adiposity is a potential confounder of the relationship between the MBDA score and RA disease activity or radiographic progression. The effects of variability in age, sex and adiposity on the MBDA score are of interest because levels of inflammation generally increase with age, even in the absence of clinical disease, male vs female sex might differentially affect the MBDA score, and adipose tissue can secrete or respond to component proteins of the MBDA score, including IL-6, leptin and TNF receptor-I. The MBDA score correlates with DAS28-CRP and is a predictor of radiographic progression in patients treated with biologic and non-biologic DMARDs. The multi-biomarker disease activity (MBDA) blood test measures 12 proteins to produce a validated score, on a scale of 1–100, that represents the level of disease activity in patients with RA. These include combinations of clinical measures (eg, the Clinical Disease Activity Index (CDAI)) and clinical and laboratory measures (e.g. Various metrics have been developed to monitor disease activity in patients with RA and support the goal of achieving remission.
0 Comments
Leave a Reply. |